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 Mycosis fungoides (MF) is a cutaneous T-cell lymphoma associated with the 
invasion of transformed mature T-cells into the skin demonstrating polymorphic atrophic 
patches, plaques, to generalized erythrodermia.  In general, the prognosis for 
advanced MF patients with metastasis to other sites has been reported to be poor even 
when treated with systemic therapies [1, 2].  Several reports of allogeneic 
hematopoietic stem cell transplantation (allo-HSCT) with both myeloablative and 
reduced-intensity conditioning regimens [3-5] suggest the efficacy of allo-HSCT for MF 
through a graft-versus-lymphoma (GVL) effect [6]. 
 In June 2004, a 26-year-old woman was admitted to our hospital because of 
generalized erythrodermia, a skin tumor of the head, and multiple lymphadenopathy.  
Her medical history started from 1996 with itchy erythema diagnosed as parapsoriasis in 
January 2001.  Skin tumors developed 3 years later on the head, diagnosed as MF on 
biopsy.  In June 2004, her disease status advanced with generalized multiple skin 
tumors and lymphadenopathy, eosinophilia (20% of WBC), and the elevation of LDH 
(367 IU/L, normal range: 119-229).  Lymph node biopsy and bone marrow analysis 
revealed the invasion of abnormal T cells, leading to a diagnosis of stage IV MF.  Since 
systemic combination (biweekly CHOP, 8 cycles) or low-dose chemotherapy did not 
elicit any clinical response, allo-HSCT was considered appropriate for the treatment of 
this patient.  In April 2005, allogeneic bone marrow transplantation from an unrelated 
donor was performed after reduced-intensity conditioning (fludarabine at 25 mg/m2/day 
for 5 days and melphalan at 70 mg/m2/day for 2 days) infusing 2.9 x 108 cells/kg of bone 
marrow cells, which resulted in the rejection of donor cells.  MF lesions that showed 
temporal regression after conditioning recurred within 5 weeks after transplantation.  
Another chemotherapy regimen with cladribine and etoposide did not lead to any 
improvement of MF after the first transplantation.  She had multiple skin tumors with 
generalized erythrodermia and lymphadenopathy. 
 Considering the refractory nature of MF in this patient, we decided to perform 
a second allo-HSCT.  In August 2005, after total body irradiation (12 Gy, 6 fractions) 
and cyclophosphamide (60 mg/kg/day, 2 days), cord blood (2.2 x 107 cells/kg, HLA 2 loci 
mismatched, from a male donor) from the Japanese Cord Blood Bank Network was 
transplanted.  For prophylaxis for graft-versus-host disease (GVHD), tacrolimus (0.03 
mg/kg, continuous infusion) was used as a single agent.  Neutrophils recovered on day 
14, and engraftment was confirmed in bone marrow by FISH analysis of sex 
chromosomes.  Platelet recovery (> 50,000/mm3 without transfusion) was observed on 
day 41.  In terms of MF regions, skin tumors, erythrodermia, and lymphadenopathy 
began to diminish during conditioning, and disappeared by the time of engraftment, 
achieving clinical complete remission.  Around day 85 after transplantation, skin 
tumors appeared again on both her legs with itchy skin regions, along with multiple 
duodenal ulcers (by endoscopic examination) and multiple areas of lymph node swelling 
(neck, axilla, mediastinum, and para-aorta by CT scan).  Skin tumor biopsy confirmed 
the relapse of MF, and histological analysis of the duodenal ulcer strongly suggested EB 
virus-associated lymphoproliferative disease.  Tacrolimus was reduced and 
discontinued within 2 weeks; then, skin tumors and skin lesions showed a gradual 
decrease in size and completely diminished by day 140 (Figure 1).  No chemotherapy 
was added.  There was no clear sign of acute or chronic GVHD even after the 
discontinuation of tacrolimus.   There was no sign of MF on her skin and no 
lymphadenopathy on CT scan at more than 23 months after the second CR, with a 
Karnofsky score of 90%.   
 Several groups described that neither conventional chemotherapy nor 
high-dose chemotherapy with autologous stem cell support was sufficient for the 
long-term remission of MF [7, 8].  Based on the successful reports of allo-HSCT for MF 
and the efficacy of the withdrawal of immunosuppressants for some relapsed MF cases, 
the important role of the GVL effect for the control of MF is suggested [9, 10].  This is 
the first report of successful CBT for advanced MF with the graft-versus-MF effect.  
Since cord blood is available for many patients through cord blood banks and the 
waiting period is relatively short, CBT could be a therapeutic option for MF patients who 
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Figure legends 
 
Figure 1.  
Skin lesions of MF before CBT (A), and those after the discontinuation of tacrolimus (B). 
Skin tumors (on the head, right eyelid, back, and upper arm) and erythroderma 
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